knowledge -WSS

knowledge

author：focus 2025-10-01 00:49:53 - browse：3

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： See how much Covid

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

The Pandemic Treaty must support building strong health systems

Congress may force more Covid

Let's speed up science by embracing open access publishing

Measles policy set amid Florida outbreak alarms vaccine proponents

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

Medicare details structure of new drug price negotiation program

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Tori Bowie and the unacceptable rates of Black maternal death

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Walensky prepares to leave CDC — and Congress — behind

HIV drugs protect against transmission, even in unprotected sex

Hollywood unions extend contract negotiations for actors

The Pandemic Treaty must support building strong health systems

Novavax promises a turnaround & Lilly roils the obesity market

HIV drugs protect against transmission, even in unprotected sex

knowledge

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

HIV drugs protect against transmission, even in unprotected sex

Flagship Pioneering startup Sonata Therapeutics lays off 21

The Pandemic Treaty must support building strong health systems

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

hotspot

entertainment

hotspot